CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Fenofibrate +1 moredrug
Likely dose
Fenofibrate 145mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03515213
NCT03515213Phase 2Completed
CompareCT.gov

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

University of California, Irvine·interventional·Posted May 3, 2018·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating Fenofibrate and Placebo for Huntington Disease. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 3, 2018
Enrollment StartApr 27, 2017
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.2 years ago

Interventions

Fenofibratedrug

145mg of fenofibrate

Placebodrug

Placebo